These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 24326534)

  • 1. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
    Kohrt HE; Thielens A; Marabelle A; Sagiv-Barfi I; Sola C; Chanuc F; Fuseri N; Bonnafous C; Czerwinski D; Rajapaksa A; Waller E; Ugolini S; Vivier E; Romagné F; Levy R; Bléry M; André P
    Blood; 2014 Jan; 123(5):678-86. PubMed ID: 24326534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.
    Du J; Lopez-Verges S; Pitcher BN; Johnson J; Jung SH; Zhou L; Hsu K; Czuczman MS; Cheson B; Kaplan L; Lanier LL; Venstrom JM
    Cancer Immunol Res; 2014 Sep; 2(9):878-89. PubMed ID: 24958280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
    Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
    Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
    Kohrt HE; Houot R; Goldstein MJ; Weiskopf K; Alizadeh AA; Brody J; Müller A; Pachynski R; Czerwinski D; Coutre S; Chao MP; Chen L; Tedder TF; Levy R
    Blood; 2011 Feb; 117(8):2423-32. PubMed ID: 21193697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
    Binyamin L; Alpaugh RK; Hughes TL; Lutz CT; Campbell KS; Weiner LM
    J Immunol; 2008 May; 180(9):6392-401. PubMed ID: 18424763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
    Terszowski G; Klein C; Stern M
    J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
    MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
    Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
    MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
    Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ
    Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells.
    Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
    Cell Immunol; 2014 Aug; 290(2):233-44. PubMed ID: 25117605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma.
    Enqvist M; Jacobs B; Junlén HR; Schaffer M; Melén CM; Friberg D; Wahlin BE; Malmberg KJ
    Front Immunol; 2019; 10():2085. PubMed ID: 31572357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.
    Wang W; Erbe AK; Alderson KA; Phillips E; Gallenberger M; Gan J; Campana D; Hank JA; Sondel PM
    Cancer Immunol Immunother; 2016 Sep; 65(9):1047-59. PubMed ID: 27392940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
    Romagné F; André P; Spee P; Zahn S; Anfossi N; Gauthier L; Capanni M; Ruggeri L; Benson DM; Blaser BW; Della Chiesa M; Moretta A; Vivier E; Caligiuri MA; Velardi A; Wagtmann N
    Blood; 2009 Sep; 114(13):2667-77. PubMed ID: 19553639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
    Inagaki A; Ishida T; Yano H; Ishii T; Kusumoto S; Ito A; Ri M; Mori F; Ding J; Komatsu H; Iida S; Ueda R
    Int J Cancer; 2009 Jul; 125(1):212-21. PubMed ID: 19358282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response.
    Makanga DR; Jullien M; David G; Legrand N; Willem C; Dubreuil L; Walencik A; Touzeau C; Gastinne T; Tessoulin B; Le Gouill S; Mahé B; Gagne K; Chevallier P; Clemenceau B; Retière C
    Oncoimmunology; 2021 Jun; 10(1):1936392. PubMed ID: 34178429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
    Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
    Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.